Jennifer A Woyach

List of Publications by Year
in descending order

108 papers	7,694 citations	147801 31 h-index	53230 85 g-index
109 all docs	109 docs citations	109 times ranked	6798 citing authors

#	Article	IF	Citations
1	Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. New England Journal of Medicine, 2014, 370, 2286-2294.	27.0	1,042
2	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2016, 374, 323-332.	27.0	785
3	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	27.0	706
4	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncology, 2015, 1, 80.	7.1	498
5	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet, The, 2020, 395, 1278-1291.	13.7	393
6	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, 127, 1117-1127.	1.4	381
7	The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood, 2012, 120, 1175-1184.	1.4	348
8	Final analysis from RESONATE: Up to six years of followâ€up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 2019, 94, 1353-1363.	4.1	305
9	Ibrutinib treatment improves T cell number and function in CLL patients. Journal of Clinical Investigation, 2017, 127, 3052-3064.	8.2	280
10	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood, 2014, 123, 1810-1817.	1.4	246
11	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2015, 21, 3705-3715.	7.0	183
12	Brutonâ€™s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood, 2014, 123, 1207-1213.	1.4	176
13	Hypertension and incident cardiovascular events following ibrutinib initiation. Blood, 2019, 134, 1919-1928.	1.4	155
14	Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 164-170.	3.6	142
15	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood, 2015, 126, 842-850.	1.4	125
16	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. Journal of Clinical Oncology, 2011, 29, 1349-1355.	1.6	124
17	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2831-2841.	7.0	123
18	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Advances, 2017, 1, 1739-1748.	5.2	123

#	Article	IF	Citations
19	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discovery, 2018, 8, 1300-1315.	9.4	115
20	Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood, 2015, 126, 471-477.	1.4	112
21	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nature Communications, 2020, 11, 4268.	12.8	112
22	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discovery, 2018, 8, 458-477.	9.4	101
23	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naÃ¯ve chronic lymphocytic leukemia. Leukemia, 2022, 36, 1171-1175.	7.2	72
24	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-NaÃ¯ve and Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 3626-3637.	1.6	71
25	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia, 2019, 33, 2527-2530.	7.2	65
26	Acalabrutinib plus Obinutuzumab in Treatment-NaÃ¯ve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discovery, 2020, 10, 394-405.	9.4	60
27	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood, 2014, 124, 3553-3560.	1.4	56
28	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 2021, 137, 3327-3338.	1.4	47
29	How I manage ibrutinib-refractory chronic lymphocytic leukemia. Blood, 2017, 129, 1270-1274.	1.4	44
30	New therapeutic advances in the management of progressive thyroid cancer. Endocrine-Related Cancer, 2009, 16, 715-731.	3.1	42
31	T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 7-15.	2.0	37
32	NCCN GuidelinesÂ® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 622-634.	4.9	33
33	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. Cell and Bioscience, 2021, 11, 197.	4.8	32
34	Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. Circulation, 2019, 139, 2594-2596.	1.6	31
35	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2021, 14, 17.	17.0	31
36	Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood, 2016, 128, 3101-3112.	1.4	30

#	Article	IF	Citations
37	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. Blood, 2017, 130, 830-830.	1.4	27
38	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Seminars in Oncology, 2016, 43, 300-310.	2.2	26
39	Use of <scp>PD</scp>â€1 (<scp>PDCD</scp>1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. British Journal of Haematology, 2019, 185, 363-366.	2.5	22
40	Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 639-639.	1.4	22
41	Patterns of resistance to B cellâ€“receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management. Hematology American Society of Hematology Education Program, 2015, 2015, 355-360.	2.5	20
42	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood, 2015, 125, 284-295.	1.4	19
43	Targeting phosphatidylinositol 3 kinase-Î² and -Î´ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 4382-4392.	5.2	18
44	EÎ¼-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. Clinical Cancer Research, 2019, 25, 6260-6273.	7.0	17
45	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 320-329.	3.8	16
46	The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3232-3232.	1.4	16
47	The regulation of tumor-suppressive microRNA, miR-126, inÂchronic lymphocytic leukemia. Cancer Medicine, 2017, 6, 778-787.	2.8	15
48	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. Blood, 2021, 138, 392-392.	1.4	15
49	Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest. Resuscitation, 2019, 142, 30-37.	3.0	14
50	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia, 2021, 35, 2854-2861.	7.2	12
51	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	1.4	12
52	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. British Journal of Haematology, 2019, 187, 399-402.	2.5	10
53	BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naÃ¯ve elderly patients with CLL. Therapeutic Advances in Hematology, 2020, 11, 204062072091299.	2.5	10
54	Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. Journal of Hematology and Oncology, 2021, 14, 36.	17.0	9

#	Article	IF	Citations
55	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. British Journal of Haematology, 2015, 170, 200-207.	2.5	8
56	Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. NAR Genomics and Bioinformatics, 2020, 2, lqaa070.	3.2	8
57	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. Blood, 2016, 128, 4387-4387.	1.4	8
58	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. Blood, 2016, 128, 55-55.	1.4	8
59	Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 691-694.	3.8	8
60	The EÂµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. Blood, 2015, 126, 2752-2752.	1.4	8
61	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. Clinics in Geriatric Medicine, 2016, 32, 175-189.	2.6	7
62	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2021, 62, 3278-3282.	1.3	7
63	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). Blood, 2019, 134, 1754-1754.	1.4	7
64	The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2920-2920.	1.4	7
65	Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib. Blood, 2020, 136, 32-33.	1.4	6
66	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Cancer Research Communications, 2021, 1, 79-89.	1.7	6
67	HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leukemia and Lymphoma, 2019, 60, 2308-2311.	1.3	5
68	Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. Blood, 2016, 128, 1259-1259.	1.4	5
69	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. Blood, 2016, 128, 3238-3238.	1.4	5
70	Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax. Blood, 2021, 138, 679-679.	1.4	5
71	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-NaÃ¯ve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. Blood, 2021, 138, 2642-2642.	1.4	5
72	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 766-774.	0.4	4

#	Article	IF	Citations
73	REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK. Blood, 2016, 128, 4399-4399.	1.4	4
74	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. Hematology American Society of Hematology Education Program, 2019, 2019, 476-481.	2.5	3
75	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2020, 26, 6187-6195.	7.0	3
76	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2021, 62, 716-721.	1.3	3
77	Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. Blood, 2015, 126, 2940-2940.	1.4	3
78	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. Nature Communications, 2021, 12, 6338.	12.8	3
79	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. Leukemia, 2022, 36, 2129-2131.	7.2	3
80	Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. Leukemia and Lymphoma, 2018, 59, 1461-1465.	1.3	2
81	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. Blood, 2019, 134, 3049-3049.	1.4	2
82	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2953-2953.	1.4	2
83	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. Blood, 2016, 128, 2040-2040.	1.4	2
84	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. Blood, 2016, 128, 4385-4385.	1.4	2
85	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. Blood, 2016, 128, 4386-4386.	1.4	2
86	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. Blood, 2016, 128, 4388-4388.	1.4	2
87	Genomics of Resistance to Targeted Therapies. Hematology/Oncology Clinics of North America, 2021, 35, 715-724.	2.2	1
88	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. Blood, 2019, 134, 3045-3045.	1.4	1
89	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood, 2020, 136, 2-3.	1.4	1
90	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. Blood, 2010, 116, 2456-2456.	1.4	1

#	Article	IF	Citations
91	Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1232-1232.	1.4	1
92	Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression. Blood, 2016, 128, 2705-2705.	1.4	1
93	Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies. Blood, 2015, 126, 317-317.	1.4	1
94	Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo. Blood, 2016, 128, 352-352.	1.4	1
95	Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia. Blood, 2019, 134, 2526-2526.	1.4	1
96	The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia. Blood, 2019, 134, 2077-2077.	1.4	1
97	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 22-23.	1.4	1
98	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. Blood, 2020, 136, 29-30.	1.4	1
99	Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. Journal of Geriatric Oncology, 2021, , .	1.0	1
100	A CAPTIVATE-ing new regimen for CLL. Blood, 2022, 139, 3229-3230.	1.4	1
101	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 2021, 35, 3287-3290.	7.2	0
102	Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). , 2021, , .		0
103	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. Blood, 2013, 122, 2872-2872.	1.4	0
104	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. Blood, 2013, 122, 2523-2523.	1.4	0
105	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies. Blood, 2015, 126, 318-318.	1.4	0
106	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. Blood, 2016, 128, 3198-3198.	1.4	0
107	LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia. Blood, 2019, 134, 3377-3377.	1.4	0
108	Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation. Blood, 2021, 138, 2252-2252.	1.4	0